The role of dipeptidyl peptidase 4 inhibitors in fat metabolism in patients with type 2 diabetes and obesity

Código QR

The role of dipeptidyl peptidase 4 inhibitors in fat metabolism in patients with type 2 diabetes and obesity

Objective. To evaluate the influence of combined therapy of sitagliptin and metformin on fat metabolism in patients with type 2 diabetes mellitus.Methods. The study included 82 patients (age, 55.3±9.1 years) with obesity and lipid metabolism disorders. None of the patients had reached their target g...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Aleksander Sergeevich Ametov, Dinara Gadgimagomedovna Gusenbekova
Formato:	article
Lenguaje:	EN RU
Publicado:	Endocrinology Research Centre 2015
Materias:	sitagliptin visceral fat fat metabolism type 2 diabetes Nutritional diseases. Deficiency diseases RC620-627
Acceso en línea:	https://doaj.org/article/b13f9ca0f1714b428c8f9802849ce023
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Efficacy and safety of metformin-sitagliptin combination for the treatment of patients with diabetes mellitus and obesity
por: Alexander Sergeevich Ametov, et al.
Publicado: (2010)

Role of Vitamin D in the Development of Obesity
por: Merino,O., et al.
Publicado: (2017)

Visceral-to-subcutaneous fat ratio as a predictor of the multiple metabolic risk factors for subjects with normal waist circumference in Korea
por: Oh YH, et al.
Publicado: (2017)

Correlation of epicardial fat and anthropometric measurements in Asian-Indians: A community based study
por: Ranjan Shetty, et al.
Publicado: (2012)

The association between fat-to-muscle ratio and metabolic disorders in type 2 diabetes
por: Dixing Liu, et al.
Publicado: (2021)

Urate-lowering effects of dipeptidyl peptidase-4 inhibitors
por: Taras S. Panevin, et al.
Publicado: (2020)

Impact of metabolic syndrome parameters and different fat depots on arterial stiffness in patients with abdominal obesity
por: Marina V. Andreevskaia, et al.
Publicado: (2021)

Subcutaneous to visceral fat ratio: a possible risk factor for metabolic syndrome and cardiovascular diseases
por: Shafqat MN, et al.
Publicado: (2018)

Experience with sitagliptin (the first DPP-4 inhibitor) application to the treatment of type 2 diabetes mellitus in the Russian Federation:Results of the DIA-DA observation program
por: Marina Vladimirovna Shestakova
Publicado: (2010)

Possible applications of gliptins (dipeptidyl peptidase-4 inhibitors) in patients with type 2 diabetes mellitus on the various modes of insulin therapy
por: Gagik Radikovich Galstyan, et al.
Publicado: (2015)

Natural dipeptidyl peptidase-IV inhibitor mangiferin mitigates diabetes- and metabolic syndrome-induced changes in experimental rats
por: Suman RK, et al.
Publicado: (2016)

The Relationship Between Abdominal Body Composition and Metabolic Syndrome After a Weight Reduction Program in Adult Men with Obesity
por: Liao CC, et al.
Publicado: (2020)

Association of Periaortic Fat and Abdominal Visceral Fat with Coronary Artery Atherosclerosis in Chinese Middle Aged and Elderly Patients Undergoing Computed Tomography Coronary Angiography
por: Jingqi Zhu, et al.
Publicado: (2021)

Optimal Cut-Off Values of Visceral Fat Area for Predicting Metabolic Syndrome Among Type 2 Diabetes Patients in Ningbo, China
por: Yang X, et al.
Publicado: (2021)

Comparative evaluation of empagliflozin, canagliflozin and sitagliptin cardioprotective properties in rats with experimental type 2 diabetes mellitus
por: A. V. Simanenkova, et al.
Publicado: (2021)

Initial investigation of efficacy and safety of a new dipeptidyl peptidase-4 inhibitor, gosogliptin, for type 2 diabetes in Russia
por: Lyudmila Viktorovna Nedosugova, et al.
Publicado: (2014)

Efficacy and safety of evogliptin versus sitagliptin as add on to metformin alone in a combined russian-korean population. Evo-combi trial
por: Alina Y. Babenko, et al.
Publicado: (2018)

Dipeptidylpeptidase-4 inhibitors in the treatment of diabetes mellitus. Possibilities of cardioprotection
por: Elena Nikolaevna Trunina, et al.
Publicado: (2011)

SP-1154, a novel synthetic TGF-β inhibitor, alleviates obesity and hepatic steatosis in high-fat diet-induced mice
por: Kisoo Pahk, et al.
Publicado: (2022)

Glomerular filtration rate and its relationship with visceral and subcutaneous adiposity: a study with patients from Northeast Brazil
por: Campello Leal,Claudia, et al.
Publicado: (2020)

Visceral fat level correction of the left ventricular hypertrophy electrocardiographic criteria
por: Szymon Salamaga, et al.
Publicado: (2021)

Salivary adiponectin concentration in healthy adult males in relation to anthropometric measures and fat distribution
por: Abdalla Mona Mohamed Ibrahim, et al.
Publicado: (2017)

The Characteristics Of Abdominal Fat Distribution In Japanese Adolescents With Type 2 Diabetes Mellitus
por: Abe Y, et al.
Publicado: (2019)

Leucine imparts cardioprotective effects by enhancing mTOR activity and mitochondrial fusion in a myocardial ischemia/reperfusion injury murine model
por: Atsushi Morio, et al.
Publicado: (2021)

Skeletal muscle mass to visceral fat area ratio is an important determinant associated with type 2 diabetes and metabolic syndrome
por: Wang Q, et al.
Publicado: (2019)

Visceral Fat Area, Not Subcutaneous Fat Area, is Associated with Cardiac Hemodynamics in Type 2 Diabetes
por: Qiu Y, et al.
Publicado: (2020)

The efficacy of therapy with DPP-4 inhibitors combined with insulin in patients with type 2 diabetes mellitus
por: Alexander Sergeevich Ametov, et al.
Publicado: (2011)

Cognitive impairment in patients with type 2 diabetes mellitus: prevalence, pathogenetic mechanisms, the effect of antidiabetic drugs
por: Olga D. Ostroumova, et al.
Publicado: (2018)

A Differential Study into Body Fat in Healthy and Hypertensive Populations Using Multiple Indexes
por: Wang R, et al.
Publicado: (2021)

Relationship Between Skeletal Muscle Mass to Visceral Fat Area Ratio and Cardiovascular Risk in Type 2 Diabetes
por: Liu D, et al.
Publicado: (2021)

Body Composition Characteristics of a Load-Capacity Model: Age-Dependent and Sex-Specific Percentiles in 5- to 17-Year-Old Children
por: Isabel Gätjens, et al.
Publicado: (2021)

Type 2 diabetes mellitus in elderly patients treated with endocrinologists in clinical practice
por: Elena V. Biryukova
Publicado: (2019)

Efficacious and safe management of type 2 diabetes mellitus using DPP-4 inhibitors
por: Alexander Sergeevich Ametov, et al.
Publicado: (2010)

Influence of Muscle Mass Area and Visceral Obesity on 30-day Mortality After Colorectal Surgery with Primary Anastomosis
por: Paulina Moctezuma-Velázquez, et al.
Publicado: (2021)

Fat cardiomyopathy in patients with severe degree of obesity. Case report
por: Sofia V. Miklishanskaya, et al.
Publicado: (2021)

The Potential of Visceral Adipose Tissue in Distinguishing Clear Cell Renal Cell Carcinoma from Renal Angiomyolipoma with Minimal Fat
por: Liu J, et al.
Publicado: (2021)

Epicardial and Perihepatic Fat as Cardiometabolic Risk Predictors in Girls with Turner Syndrome: A Cardiac Magnetic Resonance Study
por: Nanees A. Salem, et al.
Publicado: (2021)

Effect of Visceral Fat on the Amount of Hydroxyproline and Histopathological Changes on Surgical Wound Healing in Male Rat
por: K Didevar, et al.
Publicado: (2019)

Associations between Intra-Pancreatic Fat Deposition, Pancreas Size, and Pancreatic Enzymes in Health and after an Attack of Acute Pancreatitis
por: Juyeon Ko, et al.
Publicado: (2021)

Adipokines in metabolic processes regulating during obesity treatment
por: Larisa Sergeevna Litvinova, et al.
Publicado: (2014)